{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:17:28Z","timestamp":1767143848476,"version":"build-2238731810"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2014,8,6]],"date-time":"2014-08-06T00:00:00Z","timestamp":1407283200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1007\/s40264-014-0211-6","type":"journal-article","created":{"date-parts":[[2014,8,5]],"date-time":"2014-08-05T07:23:10Z","timestamp":1407223390000},"page":"723-733","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Adverse Gastrointestinal Events with Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors: Nested Case\u2013Control Study"],"prefix":"10.1007","volume":"37","author":[{"given":"Robert J.","family":"Campbell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaim M.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan E.","family":"Bronskill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Michael","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlo","family":"Whitehead","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica de L.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudeep S.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,8,6]]},"reference":[{"key":"211_CR1","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.ophtha.2008.08.012","volume":"115","author":"MS Ip","year":"2008","unstructured":"Ip MS, Scott IU, Brown GC, Brown MM, Ho AC, Huang SS, et al. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration\u2014a report by the American Academy of Ophthalmology. Ophthalmology. 2008;115:1837\u201346.","journal-title":"Ophthalmology"},{"key":"211_CR2","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432\u201344.","journal-title":"N Engl J Med"},{"key":"211_CR3","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419\u201331.","journal-title":"N Engl J Med"},{"key":"211_CR4","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMicm1005605","volume":"364","author":"D Martin","year":"2011","unstructured":"CATT Research Group, Martin D, Maguire M, Ying G, Grunwald J, Fine S, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897\u2013908.","journal-title":"N Engl J Med"},{"key":"211_CR5","first-page":"1102.e1","volume":"117","author":"PA Campochiaro","year":"2010","unstructured":"Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117:1102.e1\u20131112.e1.","journal-title":"Ophthalmology"},{"key":"211_CR6","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ophtha.2010.12.033","volume":"118","author":"MJ Elman","year":"2011","unstructured":"Elman MJ, Bressler NM, Qin H, Beck RW, 3rd Ferris FL, Friedman SM, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118:609\u201314.","journal-title":"Ophthalmology"},{"key":"211_CR7","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","volume":"96","author":"T Kamba","year":"2007","unstructured":"Kamba T, McDonald D. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96:1788.","journal-title":"Br J Cancer"},{"key":"211_CR8","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.survophthal.2009.02.003","volume":"54","author":"J Tu\u00f1\u00f3n","year":"2009","unstructured":"Tu\u00f1\u00f3n J, Ruiz-Moreno JM, Mart\u00edn-Ventura JL, Blanco-Colio LM, Lorenzo O, Egido J. Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration. Surv Ophthalmol. 2009;54:339\u201348.","journal-title":"Surv Ophthalmol"},{"key":"211_CR9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11523-009-0106-0","volume":"4","author":"KL Snider","year":"2009","unstructured":"Snider KL, Maitland ML. Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors. Targeted Oncol. 2009;4:67\u201376.","journal-title":"Targeted Oncol"},{"key":"211_CR10","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ajo.2009.06.014","volume":"148","author":"K Csaky","year":"2009","unstructured":"Csaky K, Do DV. Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies. Am J Ophthalmol. 2009;148:647\u201356.","journal-title":"Am J Ophthalmol"},{"key":"211_CR11","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/jnci\/djm086","volume":"99","author":"FA Scappaticci","year":"2007","unstructured":"Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99:1232\u20139.","journal-title":"J Natl Cancer Inst"},{"key":"211_CR12","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1200\/JCO.2010.31.9129","volume":"29","author":"TK Choueiri","year":"2011","unstructured":"Choueiri TK, Mayer EL, Je Y, Rosenberg JE, Nguyen PL, Azzi GR, et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol. 2011;29:632\u20138.","journal-title":"J Clin Oncol"},{"key":"211_CR13","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1001\/jama.2008.656","volume":"300","author":"SR Nalluri","year":"2008","unstructured":"Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008;300:2277.","journal-title":"JAMA"},{"key":"211_CR14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000314980","volume":"79","author":"S Hapani","year":"2010","unstructured":"Hapani S, Sher A, Chu D, Wu S. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology. 2010;79:27\u201338.","journal-title":"Oncology"},{"key":"211_CR15","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00228-012-1232-7","volume":"68","author":"S Taugourdeau-Raymond","year":"2012","unstructured":"Taugourdeau-Raymond S, Rouby F, Default A, Jean-Pastor MJ, French Network of Pharmacovigilance C. Bevacizumab-induced serious side-effects: a review of the french pharmacovigilance database. Eur J Clin Pharmacol. 2012;68:1103\u20137.","journal-title":"Eur J Clin Pharmacol"},{"key":"211_CR16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/OTT.S31412","volume":"5","author":"J Fuloria","year":"2012","unstructured":"Fuloria J. Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer. Onco Targets Ther. 2012;5:133\u201342.","journal-title":"Onco Targets Ther"},{"key":"211_CR17","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335\u201342.","journal-title":"N Engl J Med"},{"key":"211_CR18","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"CATT Research Group, Martin DF, Maguire MG, Fine SL, Ying G, Jaffe GJ, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388\u201398.","journal-title":"Ophthalmology"},{"key":"211_CR19","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","volume":"119","author":"U Chakravarthy","year":"2012","unstructured":"IVAN Study Investigators, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119:1399\u2013411.","journal-title":"Ophthalmology"},{"key":"211_CR20","doi-asserted-by":"crossref","first-page":"g2006","DOI":"10.1136\/bmj.g2006","volume":"348","author":"D Cohen","year":"2014","unstructured":"Cohen D. Roche and Novartis colluded over wet AMD drugs, says Italian regulator. BMJ. 2014;348:g2006.","journal-title":"BMJ"},{"key":"211_CR21","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMc063011","volume":"356","author":"G Liew","year":"2007","unstructured":"Liew G, Mitchell P. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2007;356:747\u20138.","journal-title":"N Engl J Med"},{"key":"211_CR22","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1001\/jama.2008.723","volume":"300","author":"JP Vandenbroucke","year":"2008","unstructured":"Vandenbroucke JP, Psaty BM. Benefits and risks of drug treatments. JAMA. 2008;300:2417\u20139.","journal-title":"JAMA"},{"key":"211_CR23","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1001\/archophthalmol.2010.223","volume":"128","author":"LH Curtis","year":"2010","unstructured":"Curtis LH, Hammill BG, Schulman KA, Cousins SW. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol. 2010;128:1273\u20139.","journal-title":"Arch Ophthalmol"},{"key":"211_CR24","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.ophtha.2012.05.028","volume":"119","author":"RJ Campbell","year":"2012","unstructured":"Campbell RJ, Bell CM, Paterson JM, Bronskill SE, Moineddin R, Whitehead M, et al. Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis. Ophthalmology. 2012;119:1604\u20138.","journal-title":"Ophthalmology"},{"key":"211_CR25","doi-asserted-by":"crossref","first-page":"e4203","DOI":"10.1136\/bmj.e4203","volume":"345","author":"RJ Campbell","year":"2012","unstructured":"Campbell RJ, Gill SS, Bronskill SE, Paterson JM, Whitehead M, Bell CM. Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study. BMJ. 2012;345:e4203.","journal-title":"BMJ"},{"key":"211_CR26","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/IAE.0b013e31821dc66f","volume":"31","author":"DD French","year":"2011","unstructured":"French DD, Margo CE. Age-related macular degeneration, anti-vascular endothelial growth factor agents, and short-term mortality: a postmarketing medication safety and surveillance study. Retina. 2011;31:1036\u201342.","journal-title":"Retina"},{"key":"211_CR27","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/ICU.0b013e32835f8bbe","volume":"24","author":"RJ Campbell","year":"2013","unstructured":"Campbell RJ, Bell CM, Campbell Ed, Gill SS. Systemic effects of intravitreal vascular endothelial growth factor inhibitors. Curr Opin Ophthalmol. 2013;24:197\u2013204.","journal-title":"Curr Opin Ophthalmol"},{"key":"211_CR28","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E Elm von","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP, et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806\u20138.","journal-title":"BMJ"},{"key":"211_CR29","unstructured":"Williams JI, Young W. A summary of studies on the quality of health care administration databases in Canada. In: Goel V, Williams JI, Anderson GM, Blackstien-Hirsch P, Fooks C, Naylor CD, eds. Patterns of Health Care in Ontario. The ICES Practice Atlas. 2nd ed. Ottawa: Canadian Medical Association; 1996. pp. 339\u2013345. http:\/\/www.ices.on.ca\/~\/media\/Files\/Atlases-Reports\/1996\/Patterns-of-health-care-in-Ontario-2nd-edition\/Full%20report.ashx . Accessed 8 May 2014."},{"key":"211_CR30","unstructured":"Juurlink DN, Preyra C, Croxford R, Chong A, Austin P, Tu J, et al. Canadian Institute for Health Information Discharge Abstract Database: a validation study. ICES Investigative Report. Toronto: Institute for Clinical Evaluative Sciences; 2006. http:\/\/www.ices.on.ca\/~\/media\/Files\/Atlases-Reports\/2006\/CIHI-DAD-a-validation-study\/Full%20report.ashx . Accessed 8 May 2014."},{"key":"211_CR31","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1532-5415.2010.02736.x","volume":"58","author":"A Gruneir","year":"2010","unstructured":"Gruneir A, Bell CM, Bronskill SE, Schull M, Anderson GM, Rochon PA. Frequency and pattern of emergency department visits by long-term care residents\u2014a population-based study. J Am Geriatr Soc. 2010;58:510\u20137.","journal-title":"J Am Geriatr Soc"},{"key":"211_CR32","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/archinternmed.2009.43","volume":"169","author":"SS Gill","year":"2009","unstructured":"Gill SS, Anderson GM, Fischer HD, Bell CM, Li P, Normand SLT, et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med. 2009;169:867.","journal-title":"Arch Intern Med"},{"key":"211_CR33","doi-asserted-by":"crossref","first-page":"512","DOI":"10.2337\/diacare.25.3.512","volume":"25","author":"JE Hux","year":"2002","unstructured":"Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care. 2002;25:512\u20136.","journal-title":"Diabetes Care"},{"key":"211_CR34","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0895-4356(99)00004-9","volume":"52","author":"C Cattaruzzi","year":"1999","unstructured":"Cattaruzzi C, Troncon MG, Agostinis L, Garcia Rodriguez LA. Positive predictive value of ICD-9th codes for upper gastrointestinal bleeding and perforation in the Sistema Informativo Sanitario Regionale Database. J Clin Epidemiol. 1999;52:499\u2013502.","journal-title":"J Clin Epidemiol"},{"key":"211_CR35","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00001648-199601000-00018","volume":"7","author":"DS Raiford","year":"1996","unstructured":"Raiford DS, Perez Gutthann S, Garcia Rodriguez LA. Positive predictive value of ICD-9 codes in the identification of cases of complicated peptic ulcer disease in the Saskatchewan Hospital Automated Database. Epidemiology. 1996;7:101\u20134.","journal-title":"Epidemiology"},{"key":"211_CR36","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/pds.2334","volume":"21","author":"K Moores","year":"2012","unstructured":"Moores K, Gilchrist B, Carnahan R, Abrams T. A systematic review of validated methods for identifying pancreatitis using administrative data. Pharmacoepidemiol Drug Saf. 2012;21:194\u2013202.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"211_CR37","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1503\/cmaj.1041363","volume":"172","author":"DR Urbach","year":"2005","unstructured":"Urbach DR, Stukel TA. Rate of elective cholecystectomy and the incidence of severe gallstone disease. CMAJ. 2005;172:1015\u20139.","journal-title":"CMAJ"},{"key":"211_CR38","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/aje\/154.9.854","volume":"154","author":"S Schneeweiss","year":"2001","unstructured":"Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001;154:854\u201364.","journal-title":"Am J Epidemiol"},{"key":"211_CR39","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1001\/jama.2009.683","volume":"301","author":"CM Bell","year":"2009","unstructured":"Bell CM, Hatch WV, Fischer HD, Cernat G, Paterson JM, Gruneir A, et al. Association between tamsulosin and serious ophthalmic adverse events in older men following cataract surgery. JAMA. 2009;301:1991.","journal-title":"JAMA"},{"key":"211_CR40","first-page":"178","volume-title":"Fitting models to continuous data","author":"N Breslow","year":"1987","unstructured":"Breslow N, Day N. Fitting models to continuous data. 82nd ed. France: IARC Scientific Publications; 1987. p. 178\u2013229.","edition":"82"},{"key":"211_CR41","first-page":"811","volume-title":"Novel approaches to pharmacoepidemiology study design and statistical analysis","author":"S Suissa","year":"2005","unstructured":"Suissa S. Novel approaches to pharmacoepidemiology study design and statistical analysis. England: Wiley; 2005. p. 811\u201329."},{"key":"211_CR42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/01621459.1983.10477915","volume":"78","author":"N Breslow","year":"1983","unstructured":"Breslow N, Lubin J, Marek P, Langholz B. Multiplicative models and cohort analysis. J Am Stat Assoc. 1983;78:1\u201312.","journal-title":"J Am Stat Assoc"},{"key":"211_CR43","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2288-5-5","volume":"5","author":"V Essebag","year":"2005","unstructured":"Essebag V, Platt RW, Abrahamowicz M, Pilote L. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol. 2005;5:5.","journal-title":"BMC Med Res Methodol"},{"key":"211_CR44","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2307\/2345280","volume":"140","author":"F Liddell","year":"1977","unstructured":"Liddell F, McDonald J, Thomas D. Methods of cohort analysis: appraisal by application to asbestos mining. J R Stat Soc Ser A. 1977;140:469\u201391.","journal-title":"J R Stat Soc Ser A"},{"key":"211_CR45","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28:3083\u2013107.","journal-title":"Stat Med"},{"key":"211_CR46","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMe1213569","volume":"367","author":"JM Drazen","year":"2012","unstructured":"Drazen JM, Curfman GD, Baden LR, Morrissey S. Compounding errors. N Engl J Med. 2012;367:2436\u20137.","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.1007\/s40264-014-0217-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2014,8,22]],"date-time":"2014-08-22T00:00:00Z","timestamp":1408665600000}}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-014-0211-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-014-0211-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-014-0211-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:41:33Z","timestamp":1559490093000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-014-0211-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,6]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["211"],"URL":"https:\/\/doi.org\/10.1007\/s40264-014-0211-6","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,6]]}}}